Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984299 | 0.63 | TSHR (0.45) | MEN1KMT2AHPGDSMN1; SMN2TSHR | |
| SCHEMBL5120484 | 0.63 | SLC6A2 (0.50) | MEN1KMT2AHPGDRAB9ALMNA | |
| SCHEMBL9262011 | 0.63 | ALDH1A1 (0.43) | MEN1KMT2AHPGDRAB9APKM | |
| SCHEMBL31213800 | 0.63 | MEN1 (0.45) | MEN1KMT2ARAB9APKMTSHR | |
| SCHEMBL9831628 | 0.62 | HPGD (0.56) | MEN1KMT2AHPGDSMN1; SMN2LMNA | |
| SCHEMBL29907650 | 0.61 | TSHR (0.41) | KMT2AHPGDL3MBTL1TSHRALDH1A1 | |
| SCHEMBL9830476 | 0.60 | HTT (0.45) | MEN1KMT2ATSHRALDH1A1MAPT | |
| SCHEMBL19953540 | 0.60 | MEN1 (0.44) | MEN1KMT2AHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL9830654 | 0.60 | ALDH1A1 (0.41) | MEN1KMT2AHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL7950190 | 0.59 | MEN1 (0.58) | MEN1KMT2AHPGDRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-4005637-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | MEN1 2070/4885KMT2A 540/4885HPGD 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.